Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Axial Therapeutics, a US-based neurological disease therapy developer linked to University of Tokyo, has closed a $37.3m series C round co-led by University of Tokyo’s Innovation Platform and OneVentures. The round included Taiho Ventures, the investment arm of pharmaceutical firm Taiho, as well as Autism Impact Fund, Corundum Systems Biology, Longwood Fund, Seventure Partners and…

The rest of this content is only accessible to Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.